鄰近類別 類別統計 近3年內發表的文件:10(55.56%) 含全文筆數:18(100.00%) 文件下載次數統計 下載大於0次:18(100.00%) 下載大於100次:17(94.44%) 檔案下載總次數:3908(100.00%) 最後更新時間: 2024-12-12 20:55 上傳排行 資料載入中..... 下載排行 資料載入中..... 最近上傳 Macrophage-mediated controlled rele... Targeting cathepsin S promotes acti... Lysosomal-targeted doxorubicin deli... How to deal with frenemy NRF2: Targ... Synthesis and structure–activity re... The synergistic inhibition of coron... MiR-455-5p suppresses PDZK1IP1 to p... The synergistic inhibition of coron... Lon upregulation contributes to cis... Discovery of potential neuroprotect...

跳至: (選擇年份) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (選擇月份) January February March April May June July August September October November December 或輸入年份:

由新到舊排序 由最舊的開始

顯示項目1-18 / 18. (共1頁) 1  每頁顯示[10|25|50]項目

日期	題名	關聯
2024-06-24	Macrophage-mediated controlled release of cysteine protease inhibitor from PLGA-PEG/hydroxyapatite microspheres for targeting cathepsin S in Alzheimer's disease	European Polymer Journal. 2024 Jun 24;214:Article number 113151.
2024-05-09	Targeting cathepsin S promotes activation of OLF1-BDNF/TrkB axis to enhance cognitive function	Journal of Biomedical Science. 2024 May 09;31:Article number 46.
2023-11	Lysosomal-targeted doxorubicin delivery using RBC-derived vesicles to overcome drug-resistant cancer through mitochondrial-dependent cell death	Pharmacological Research. 2023 Nov;197:Article number 106945.
2023-03-28	Synthesis and structure–activity relationship of salvinal derivatives as potent microtubule inhibitors	International Journal of Molecular Sciences. 2023 Mar 28;24(7):Article number 6386.
2023-02-28	How to deal with frenemy NRF2: Targeting NRF2 for chemoprevention and cancer therapy	Journal of Food and Drug Analysis. 2023 Feb 28;31(3):387-407.
2023-02-03	MiR-455-5p suppresses PDZK1IP1 to promote the motility of oral squamous cell carcinoma and accelerate clinical cancer invasion by regulating partial epithelial-to-mesenchymal transition	Journal of Experimental and Clinical Cancer Research. 2023 Feb 3;42:Article number 40.
2023-01-19	The synergistic inhibition of coronavirus replication and induced cytokine production by ciclesonide and the tylophorine-based compound dbq33b [Erratum:Pharmaceutics. 2022 Jul 21;14(7):Article number 1511.]	Pharmaceutics. 2023 Jan 19;15(2):Article number 342.
2022-07-21	The synergistic inhibition of coronavirus replication and induced cytokine production by ciclesonide and the tylophorine-based compound dbq33b	Pharmaceutics. 2022 Jul 21;14(7):Article number 1511.
2022-03-16	Lon upregulation contributes to cisplatin resistance by triggering NCLX-mediated mitochondrial Ca2+ release in cancer cells	Cell Death and Disease. 2022 Mar 16;13(3):Article number 241.
2022-03-02	Discovery of potential neuroprotective agents against paclitaxel-induced peripheral neuropathy	Journal of Medicinal Chemistry. 2022 Mar 2;65(6):4767-4782.
2021-12-14	A novel NRF2/ARE inhibitor gossypol induces cytotoxicity and sensitizes chemotherapy responses in chemo-refractory cancer cells	Journal of Food and Drug Analysis. 2021 Dec 14;29(4):638-652.
2021-11-09	MicroRANs: Their role in metabolism, tumor microenvironment, and therapeutic implications in head and neck squamous cell carcinoma	Cancers. 2021 Nov 9;13(22):Article number 5604.
2021-08-13	Remdesivir and cyclosporine synergistically inhibit the human coronaviruses OC43 and SARS-CoV-2	Frontiers in Pharmacology. 2021 Aug 13;12:Article number 706901.
2021-06	Investigating the association between serum human papillomavirus type 16 E7 antibodies and risk of head and neck cancer	Cancer Medicine. 2021 Jun;10(12):4075-4086.
2021-03-11	c-MYC-directed NRF2 drives malignant progression of head and neck cancer via glucose-6-phosphate dehydrogenase and transketolase activation	Theranostics. 2021 Mar 11;11(11):5232-5247.
2021-03-04	Targeting lysosomal cysteine protease cathepsin S reveals immunomodulatory therapeutic strategy for oxaliplatin-induced peripheral neuropathy	Theranostics. 2021 Mar 4;11(10):4672-4687.
2021-03-01	Phase I dose escalation study of sorafenib plus S-1 for advanced solid tumors	Scientific Reports. 2021 Mar 1;11:Article number 4834.
2021-02-24	New insights into oral squamous cell carcinoma: From clinical aspects to molecular tumorigenesis	International Journal of Molecular Sciences. 2021 Feb 24;22(5):Article number 2252.

顯示項目1-18 / 18. (共1頁) 1  每頁顯示[10|25|50]項目